BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//LifeSci Events - ECPv6.15.11//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:LifeSci Events
X-ORIGINAL-URL:https://lifescievents.com
X-WR-CALDESC:Events for LifeSci Events
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20260308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20261101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20270314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20271107T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260617T140000
DTEND;TZID=America/New_York:20260617T160000
DTSTAMP:20260625T104155
CREATED:20260330T170509Z
LAST-MODIFIED:20260602T121103Z
UID:2966-1781704800-1781712000@lifescievents.com
SUMMARY:Ocular Therapeutix In-Person and Virtual Investor Day 2026 Featuring Retinal Disease KOLs
DESCRIPTION:Please join Ocular Therapeutix™ for its 2026 Investor Day featuring presentations from Ocular’s senior leadership and roundtable discussions with prominent retinal disease Key Opinion Leaders (KOLs)\, followed by a live Q&A session. In-person attendees are invited to join Ocular’s leadership team for a networking reception to conclude the event. \nThe prominent retinal disease KOLs participating in Ocular’s Investor Day include: \n\nDr. Arshad M. Khanani MD\, MA\, FASRS: Managing Partner\, Director of Clinical Research and Director of Fellowship\, Sierra Eye Associates; Clinical Professor\, University of Nevada\, Reno School of Medicine.\nDr. Lejla Vajzovic\, MD\, FASRS: Professor of Ophthalmology at Duke University School of Medicine.\nDr. Darius M. Moshfeghi\, MD: Chief of the Retina Division at Byers Eye Institute of Stanford University School of Medicine.\n\nPresentations from Company leadership and KOL discussions will focus on regulatory updates regarding the NDA submission plan for AXPAXLI in wet AMD; a review of the ongoing SOL-R and SOL-X trials in wet AMD; an update on the registrational program for AXPAXLI in diabetic retinopathy; and an overview of the planned commercialization strategy for AXPAXLI in wet AMD\, if approved. Watch the webcast by clicking this link and logging in with the email address you used to register: https://lifescievents.com/event/sw02gl7/.
URL:https://lifescievents.com/event/sw02gl7/
LOCATION:Midtown\, New York and Live Webcast\, Midtown\, New York and Live Webcast
ATTACH;FMTTYPE=image/png:https://lifescievents.com/wp-content/uploads/2026/03/Ocular-1-1.png
END:VEVENT
END:VCALENDAR